Vanda Pharmaceuticals (VNDA) Gains from Sales and Divestitures (2010 - 2018)
Vanda Pharmaceuticals recorded quarterly Gains from Sales and Divestitures of $475367.0 in Q1 2018, up 31.2% quarter-over-quarter from $362313.0 in Q4 2017, and up 36.79% year-over-year from $347504.0 in Q1 2017.
Vanda Pharmaceuticals' Gains from Sales and Divestitures history runs 8 years deep, the most recent figure standing at $475367.0 for Q1 2018.
- In Q1 2018, Gains from Sales and Divestitures rose 36.79% year-over-year to $475367.0; the TTM figure through Mar 2018 stood at $475367.0 (up 36.79% YoY), while the FY2017 annual figure was $362313.0, up 25.95% from the prior year.
- Gains from Sales and Divestitures came in at $475367.0 for Q1 2018 at Vanda Pharmaceuticals, up from $362313.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $475367.0 in Q1 2018 to a low of $209562.0 in Q1 2014.
- A 5-year average of $282623.5 and a median of $287666.0 in 2016 frame the typical range for Gains from Sales and Divestitures.
- On a YoY basis, Gains from Sales and Divestitures climbed as much as 37.48% in 2014 and fell as far as 4.16% in 2014.
- Vanda Pharmaceuticals' Gains from Sales and Divestitures stood at $209562.0 in 2014, then rose by 10.27% to $231093.0 in 2015, then increased by 24.48% to $287666.0 in 2016, then increased by 25.95% to $362313.0 in 2017, then surged by 31.2% to $475367.0 in 2018.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $475367.0, $362313.0, and $356127.0 for Q1 2018, Q4 2017, and Q3 2017 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 475,367.00 |
| Mar 31, 2018 | 475,367.00 |
| Dec 31, 2017 | 362,313.00 |
| Dec 31, 2017 | 362,313.00 |
| Sep 30, 2017 | 356,127.00 |
| Sep 30, 2017 | 356,127.00 |
| Jun 30, 2017 | 350,004.00 |
| Jun 30, 2017 | 350,004.00 |
| Mar 31, 2017 | 347,504.00 |
| Mar 31, 2017 | 347,504.00 |
| Dec 31, 2016 | 287,666.00 |
| Dec 31, 2016 | 287,666.00 |
| Sep 30, 2016 | 287,666.00 |
| Sep 30, 2016 | 287,666.00 |
| Jun 30, 2016 | 287,666.00 |
| Jun 30, 2016 | 287,666.00 |
| Mar 31, 2016 | 287,666.00 |
| Mar 31, 2016 | 287,666.00 |
| Dec 31, 2015 | 231,093.00 |
| Dec 31, 2015 | 231,093.00 |
| Sep 30, 2015 | 231,093.00 |
| Sep 30, 2015 | 231,093.00 |
| Jun 30, 2015 | 231,093.00 |
| Jun 30, 2015 | 231,093.00 |
| Mar 31, 2015 | 231,093.00 |
| Mar 31, 2015 | 231,093.00 |
| Dec 31, 2014 | 209,562.00 |
| Dec 31, 2014 | 209,562.00 |
| Sep 30, 2014 | 209,562.00 |
| Sep 30, 2014 | 209,562.00 |
| Jun 30, 2014 | 209,562.00 |
| Jun 30, 2014 | 209,562.00 |
| Mar 31, 2014 | 209,562.00 |
| Mar 31, 2014 | 209,562.00 |
| Dec 31, 2013 | 201,186.00 |
| Dec 31, 2013 | 201,186.00 |
| Sep 30, 2013 | 152,436.00 |
| Sep 30, 2013 | 152,436.00 |
| Jun 30, 2013 | 152,436.00 |
| Jun 30, 2013 | 152,436.00 |
| Mar 31, 2013 | 152,436.00 |
| Mar 31, 2013 | 152,436.00 |
| Dec 31, 2011 | 2,500.00 |
| Dec 31, 2011 | 2,500.00 |
| Dec 31, 2010 | 2,500.00 |
| Dec 31, 2010 | 2,500.00 |